Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
RGD Peptide Tracers
Overview
RGD peptide tracers are short synthetic peptides containing the arginine-glycine-aspartic acid (RGD) tripeptide sequence, which binds to integrin receptors, particularly alphavbeta3, conjugated to positron or gamma-emitting radioisotopes. Alphavbeta3 integrin is upregulated on angiogenic endothelium and many cancer cells, making RGD tracers useful for imaging tumor angiogenesis, metastatic disease, and potentially cardiovascular pathology.
Mechanism of Action
Cyclic RGD peptides and multimeric constructs have been developed to improve binding affinity and tumor retention.
Research Summary & Key Findings
Multiple RGD tracers including 18F-galacto-RGD, 68Ga-NODAGA-RGD, and 18F-fluciclatide have undergone clinical evaluation in cancer imaging trials, with results demonstrating tracer uptake correlating with integrin expression and tumor angiogenesis. Despite promising Phase 1 and Phase 2 data published in the Journal of Nuclear Medicine and Clinical Cancer Research between 2005 and 2016, regulatory approval has not been achieved, in part due to variable tumor uptake and lack of clear clinical decision-making impact.
Clinical Status
RGD Peptide Tracers is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.
Administration Routes
References
Primary literature
- PubMed: "RGD Peptide Tracers"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "RGD Peptide Tracers"
Registered interventional and observational studies, including status and phase.
- PubChem: "RGD Peptide Tracers"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Diagnostic
Pentagastrin
FDA ApprovedA synthetic pentapeptide containing the C-terminal tetrapeptide sequence of gastrin (Trp-Met-Asp-Phe-NH2) linked to beta...
View detailsGadopentetate Peptide Conjugates
Research PhaseGadopentetate peptide conjugates consist of the gadolinium-based contrast agent gadopentetate dimeglumine chemically lin...
View detailsDOTATATE (Ga-68)
FDA ApprovedGallium-68 DOTATATE is a radiolabeled somatostatin analog consisting of an octapeptide (Tyr3-octreotate) conjugated to t...
View detailsBombesin Analog Tracers
In Clinical TrialsBombesin analog tracers are synthetic peptides based on the 14-amino acid amphibian peptide bombesin or its mammalian co...
View detailsNo lawful pathway today
RGD Peptide Tracers is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Join the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.